Completed PHASE4 INTERVENTIONAL 2-arm NCT01455129

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China (Tie-COPD)

Early Intervention With Tiotropium （Spiriva） in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial

Sponsor: Boehringer Ingelheim

Conditions Chronic Obstructive Pulmonary Disease

Interventions Tiotropium placebo

Updated 5 times since 2017 Last updated: Aug 10, 2016 Started: Nov 30, 2011 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Obstructive Pulmonary Disease and is currently completed. Boehringer Ingelheim leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Rundo International Pharmaceutical Research & Development Co.,Ltd.
The First Affiliated Hospital of Guangzhou Medical University

Data source: The First Affiliated Hospital of Guangzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chenzhou, China , Chongqing, China , Foshan, China , Guangzhou, China , Guiyang, China , Huizhou, China , Shanghai, China , Shaoguan, China and 4 more locations